List of Excipients in Branded Drug ERGOCALCIFEROL CAPSULES,

Generic Drugs Containing ERGOCALCIFEROL CAPSULES,

Company	Ingredient	NDC	Excipient
Epic Pharma LLC	ergocalciferol capsules,	42806-547	BUTYLATED HYDROXYANISOLE
Epic Pharma LLC	ergocalciferol capsules,	42806-547	D&C YELLOW NO. 10
Epic Pharma LLC	ergocalciferol capsules,	42806-547	DIMETHICONE
Epic Pharma LLC	ergocalciferol capsules,	42806-547	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in ERGOCALCIFEROL CAPSULES,?

# Of NDCs	Excipient
8	BUTYLATED HYDROXYANISOLE
8	D&C YELLOW NO. 10
8	DIMETHICONE
8	FD&C BLUE NO. 1

Ergocalciferol Capsules: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 3, 2026

Ergocalciferol capsules are a low-cost vitamin D2 dosage form with limited active-ingredient differentiation. Commercial value depends on excipient selection, stability, capsule-shell design, dose flexibility, labeling, channel strategy, and manufacturing economics. The strongest opportunities are high-dose prescription capsules, vegetarian or allergen-controlled softgels, pediatric and compounded-dose formats, and products with improved light and oxygen protection.

What is the FDA status of ergocalciferol capsules?

Ergocalciferol, also called vitamin D2, is marketed in prescription and nonprescription products. Prescription products commonly contain 1.25 mg ergocalciferol, equivalent to 50,000 IU, in a capsule or softgel. FDA-approved products and listed drug products are identified through FDA Drugs@FDA, the Orange Book, and DailyMed records.[1-3]

Attribute	Commercial position
Active ingredient	Ergocalciferol, vitamin D2
Common high dose	1.25 mg, equivalent to 50,000 IU
Common dosage form	Soft gelatin capsule or hard capsule
Main uses	Vitamin D deficiency, hypoparathyroidism, refractory rickets, selected malabsorption-related conditions
FDA pathway	NDA-listed products, ANDA generics, OTC dietary supplements, and compounded products
Primary regulatory risk	Content uniformity, potency stability, light and oxygen sensitivity, labeling and dose confusion
Main commercial channel	Prescription generic, retail supplement, hospital, specialty pharmacy, and compounding

Ergocalciferol capsules do not face the biologic-product issues associated with biosimilars. They are small-molecule products. A competing product normally enters through an ANDA, a suitability petition where applicable, an NDA, or the dietary-supplement framework, depending on the product's dosage, claims, and regulatory status.

What excipients are used in ergocalciferol capsules?

The excipient system depends on whether the product is a softgel, hard capsule, tablet, or liquid-filled capsule. Vitamin D2 is highly lipophilic, so oil-based systems are common. Published labels for ergocalciferol products identify combinations of oils, gelatin, glycerin, colorants, titanium dioxide, and other capsule-shell or fill materials.[2,3]

Typical softgel excipient system

Excipient class	Examples	Primary function
Lipid vehicle	Corn oil, soybean oil, medium-chain triglycerides, sunflower oil, sesame oil	Solubilizes or disperses ergocalciferol
Capsule shell	Gelatin	Forms the softgel barrier
Plasticizer	Glycerin, sorbitol, or mixtures	Controls shell flexibility
Purified water	Water	Hydrates and processes gelatin shell
Opacifier	Titanium dioxide or alternative opacifier	Reduces light transmission
Colorant	Approved dyes or mineral pigments	Product identification and appearance
Antioxidant	Tocopherol, ascorbyl palmitate, or other permitted antioxidant	Limits oxidative degradation
Chelator	Where justified and permitted	Controls trace-metal catalyzed oxidation

The commercial formulation objective is not simply to dissolve ergocalciferol. It is to maintain assay, content uniformity, dissolution or dispersion, capsule integrity, and appearance throughout shelf life.

Hard-capsule and dry-fill systems

A hard capsule may use a powder blend or a lipid-containing liquid fill. Potential excipients include microcrystalline cellulose, lactose, starches, colloidal silicon dioxide, magnesium stearate, and a solubilized or adsorbed vitamin D2 concentrate. Dry systems can reduce gelatin-shell complexity but introduce dose-uniformity and powder-flow risks at the microgram-to-milligram active range.

For a 50,000 IU capsule, the active ingredient mass is only 1.25 mg. That creates a high dilution factor. The formulation must control segregation, blend uniformity, electrostatic behavior, and sampling error. A liquid-fill or pre-diluted vitamin D2 concentrate may provide a more reliable manufacturing platform than direct blending of neat ergocalciferol.

How should an excipient strategy be designed for vitamin D2 capsules?

A robust strategy begins with the degradation profile and target market.

1. Select the lipid vehicle

Corn oil is familiar and inexpensive, but it can create allergen, GMO, and consumer-perception issues. Medium-chain triglycerides offer a more standardized lipid source and may support vegetarian softgel positioning if paired with a non-gelatin shell. Sunflower oil can support allergen-controlled or clean-label claims, subject to market-specific substantiation.

The vehicle should be screened for:

• Ergocalciferol solubility and homogeneity
• Peroxide value and oxidative stability
• Interaction with capsule-shell materials
• Fill viscosity and pumpability
• Compatibility with antioxidants
• Supply continuity and geographic sourcing
• Labeling implications for allergens and genetically modified materials

2. Protect against light and oxygen

Vitamin D2 is sensitive to degradation from light and oxidation. A clear capsule may be commercially attractive but creates a higher packaging burden. Opaque or tinted shells, light-resistant bottles, foil blisters, nitrogen-controlled filling, and low-peroxide oils can reduce risk.

The preferred stability package should be established through forced-degradation and real-time studies. Relevant studies should assess assay, degradation products, dissolution or dispersion, fill uniformity, shell brittleness, leakage, and color change.

3. Control shell composition

Gelatin softgels are the lowest-friction platform for manufacturing and consumer familiarity. They also exclude vegan consumers and can create religious, animal-origin, and supply-chain constraints.

Alternative shell options include:

• Pullulan
• Modified starch
• Hydroxypropyl methylcellulose
• Carrageenan-based systems
• Other non-gelatin capsule technologies

These alternatives can support vegetarian or vegan positioning, but they may alter oxygen permeability, moisture transfer, sealing, machinability, and stability. A non-gelatin capsule is commercially meaningful only if the product maintains equivalent shelf life and manufacturing yield.

4. Reduce dose variability

At high dilution, ergocalciferol content uniformity is a central critical quality attribute. The manufacturer should use a validated concentrate, controlled addition sequence, adequate mixing, and in-process sampling based on blend homogeneity rather than relying only on finished-product testing.

A liquid-fill softgel can reduce powder segregation, but it creates other risks, including fill-weight control, leakage, shell migration, and interaction between the fill and shell.

What formulations are protected by patents?

Ergocalciferol itself is an old active ingredient, and basic composition-of-matter protection is not commercially relevant. The principal intellectual-property opportunities are formulation-specific.

Potentially protectable subject matter includes:

• A defined oil vehicle or excipient ratio
• A non-gelatin capsule shell
• A stabilized ergocalciferol concentrate
• A specific antioxidant system
• A light-protective capsule or package
• A controlled-release dosage form
• A pediatric liquid-fill capsule
• A combination product with calcium or another nutrient
• A manufacturing process that improves content uniformity
• A defined impurity profile or stability performance
• A method of treating a specified deficiency population

The practical strength of these claims depends on whether the excipient combination produces an unexpected stability, bioavailability, manufacturability, or patient-use result. Broad claims covering ergocalciferol with conventional oils, gelatin, glycerin, or common antioxidants would face substantial prior-art risk.

Patent and exclusivity position

Protection category	Likely status for conventional ergocalciferol capsules
Active-ingredient patent	Generally unavailable for the old vitamin D2 molecule
Basic capsule composition	Weak unless tied to a defined technical result
Formulation patent	Possible for unusual vehicle, shell, stabilization, or release profile
Manufacturing patent	Possible for validated uniformity or stability process
Method-of-use patent	Possible but difficult around established vitamin D indications
Regulatory exclusivity	Product-specific; must be checked in current FDA records
Orange Book listing	Depends on the individual prescription product and active listed patents

A company should not assume that all marketed ergocalciferol products have meaningful Orange Book patent protection. The Orange Book lists patents and exclusivity associated with specific approved products, not every patent that may relate to a vitamin D2 formulation.[1] A current product-by-product review is required before relying on any expiration date, Paragraph IV strategy, or 30-month litigation stay.

When does ergocalciferol capsule exclusivity expire?

There is no single expiration date for all ergocalciferol capsules. Conventional vitamin D2 products may have no meaningful remaining active-ingredient patent protection, while a particular formulation, manufacturing method, or delivery system could have separate protection.

Exclusivity issue	Commercial implication
Old active ingredient	Usually does not block generic development
Listed formulation patent	May require Paragraph IV, section viii, or patent-certification analysis
Method-of-use patent	Relevant only to the patented indication and labeling strategy
New dosage form	Could support a later-filed patent estate
NDA exclusivity	Must be confirmed in Drugs@FDA
OTC supplement	Not generally protected through Orange Book exclusivity

A generic applicant targeting an approved prescription capsule would typically evaluate the reference listed drug, inactive ingredients, dosage form, strength, labeling, and bioequivalence pathway. If a listed patent is present, the applicant may file a Paragraph IV certification. A Paragraph IV notice can trigger patent litigation and, in qualifying circumstances, a 30-month stay under the Hatch-Waxman framework.[4]

What generic entry risks exist for ergocalciferol capsules?

Generic entry risk is high for conventional 50,000 IU capsules because the product has a simple active ingredient, established clinical use, and limited formulation complexity. The main barriers are operational rather than fundamental.

High-risk areas for an incumbent

• Multiple ANDA applicants can target the same high-volume strength.
• Retail and mail-order pharmacies can substitute low-cost products.
• The active ingredient has limited differentiation.
• Contract manufacturers can produce softgels at scale.
• Supplement brands can compete below prescription pricing.
• Payers may prefer generic vitamin D2 or vitamin D3 products.

Barriers that can delay entry

• Difficult content-uniformity validation
• Incompatible inactive ingredients
• Capsule-shell leakage or brittleness
• Vitamin D2 degradation during accelerated stability
• Complex reference-product matching
• Shortage of qualified softgel manufacturing capacity
• Patent claims covering a differentiated formulation
• Regulatory limitations on excipient substitution

A conventional capsule without a meaningful formulation or manufacturing advantage is more exposed to price erosion than a product with documented stability, a differentiated shell, or a specialized patient population.

How does ergocalciferol compare with cholecalciferol capsules?

Ergocalciferol is vitamin D2. Cholecalciferol is vitamin D3. The products compete in deficiency treatment, supplements, institutional purchasing, and retail channels, but they are not interchangeable for every commercial or clinical purpose.

Factor	Ergocalciferol, vitamin D2	Cholecalciferol, vitamin D3
Source positioning	Often associated with yeast or fungal origin, though source varies	Commonly associated with animal-derived or synthetic sources
Prescription high-dose use	Established 50,000 IU format	Also widely marketed
Consumer demand	Strong in selected vegan and prescription segments	Generally stronger in mainstream supplements
Formulation	Oil-based softgels and hard capsules	Broad range of softgels, tablets, liquids, and gummies
Competitive intensity	High	Very high
Differentiation opportunity	Vegetarian source, stability, high-dose clinical format	Broad consumer formats and combination products
Patent leverage	Usually limited for basic product	Usually limited for basic product

Commercial positioning for vitamin D2 is strongest where source, labeling, prescription status, or specific clinical use matters. A vitamin D2 product should not rely solely on the active ingredient for differentiation.

What excipient opportunities have the highest commercial value?

Vegetarian and vegan softgels

A non-gelatin shell combined with a plant-based oil can address a defined consumer segment. The commercial proposition is stronger when supported by certifications, transparent sourcing, and a capsule that matches gelatin-softgel performance.

Allergen-controlled products

Replacing corn, soybean, or sesame oil with a selected alternative can reduce labeling complexity. The manufacturer must control cross-contact and support the claim through supplier qualification and production controls.

Pediatric and geriatric formats

High-dose capsules are poorly suited to patients who cannot swallow. Commercial opportunities include smaller capsules, sprinkle-compatible units, liquid-fill capsules, and lower-dose products. These products require careful attention to dose accuracy, accidental overexposure, palatability, and child-resistant packaging.

Stabilized high-potency products

A low-peroxide lipid vehicle, antioxidant system, opaque shell, and high-barrier package can support a longer shelf life or lower storage sensitivity. Any marketing claim should be tied to comparative stability data.

Unit-dose institutional packaging

Blistered or unit-dose capsules can reduce medication errors, improve pharmacy handling, and support hospitals, long-term-care facilities, and specialty pharmacies. Packaging is an important part of the product strategy because vitamin D dosing errors can be clinically significant.

Combination products

Ergocalciferol may be combined with calcium, magnesium, or other nutritional ingredients. Combination products can increase average selling price but create additional compatibility, dissolution, labeling, and regulatory requirements. A formulation patent may be more defensible where the combination solves a defined stability or administration problem.

What manufacturing and intellectual-property barriers affect commercialization?

Softgel production requires specialized equipment, gelatin or alternative-shell expertise, controlled fill viscosity, and reliable drying conditions. A company without internal capacity may use a contract development and manufacturing organization, but capacity, minimum batch size, and technical transfer can affect launch timing.

The most defensible manufacturing claims would normally relate to a measurable technical outcome, such as:

• Reduced assay variability across commercial-scale batches
• Lower peroxide formation
• Improved shell integrity
• Reduced ergocalciferol migration into the capsule shell
• Improved stability under light exposure
• More consistent dissolution after long-term storage

A patent portfolio combining formulation claims, process claims, and packaging claims is stronger than a single broad excipient claim. Trade-secret protection may be more effective for mixing order, concentrate preparation, oxygen-control parameters, and softgel drying conditions.

Which commercial strategy is most attractive?

Strategy	Margin potential	Regulatory complexity	Competitive exposure	Assessment
Standard 50,000 IU generic softgel	Low to moderate	Moderate	High	Volume-driven
Vegan high-dose softgel	Moderate to high	Moderate	Moderate	Stronger differentiation
Pediatric liquid-fill capsule	Moderate to high	High	Moderate	Requires dose and safety discipline
Stability-enhanced prescription product	Moderate to high	High	Moderate	Defensible if supported by data
OTC low-dose supplement	Low to moderate	Lower than NDA product	Very high	Brand and channel dependent
Unit-dose institutional product	Moderate	Moderate	Moderate	Packaging and supply reliability matter
Calcium/vitamin D combination	Moderate	Moderate to high	High	Useful for portfolio expansion

The most attractive near-term opportunity is a high-dose, non-gelatin, light-protected softgel with a validated low-peroxide lipid system and unit-dose packaging. The product should target a defined prescription, institutional, or specialty-pharmacy segment rather than compete solely on retail price.

Key Takeaways

• Ergocalciferol capsules are technically simple but commercially vulnerable to substitution and price erosion.
• Oil-based fills are generally the most practical platform for vitamin D2.
• Content uniformity, oxidation, light exposure, and capsule-shell compatibility are the critical formulation risks.
• Vegan shells, allergen-controlled oils, pediatric formats, unit-dose packaging, and stability-enhanced products offer the clearest differentiation.
• Basic ergocalciferol composition claims are unlikely to provide meaningful protection because vitamin D2 is an established active ingredient.
• Formulation, manufacturing, and packaging patents may be valuable when tied to measurable technical performance.
• Generic entry risk is high for conventional 50,000 IU capsules.
• Orange Book status, listed patents, Paragraph IV exposure, and expiration dates must be assessed for the specific reference product rather than the active ingredient generally.
• Vitamin D3 creates strong commercial competition, so vitamin D2 products need a defined source, formulation, regulatory, or channel advantage.

FAQs

Can ergocalciferol capsules use a vegan capsule shell?

Yes. A manufacturer can evaluate pullulan, modified starch, hydroxypropyl methylcellulose, or other non-gelatin systems. The shell must meet stability, leakage, dissolution, oxygen-transfer, and manufacturing requirements.

Which oil is best for ergocalciferol softgels?

There is no universal best oil. Medium-chain triglycerides, sunflower oil, corn oil, soybean oil, and other lipid vehicles should be compared for solubility, peroxide value, viscosity, shell compatibility, supply, and labeling impact.

Are vitamin D2 capsule excipients patentable?

An excipient combination may be patentable when it is novel and produces a non-obvious technical result. Conventional gelatin, glycerin, vegetable oil, and colorant combinations generally provide limited patent strength without unexpected performance data.

Can a vitamin D2 supplement use prescription-level 50,000 IU dosing?

The regulatory classification depends on the product's intended use, claims, dosage, labeling, and applicable jurisdiction. A high-dose product positioned for disease treatment may require an approved drug pathway rather than a dietary-supplement approach.

Is ergocalciferol more commercially attractive than cholecalciferol?

Vitamin D3 generally has broader consumer demand and heavier competition. Vitamin D2 can be attractive where prescription use, vegetarian sourcing, fungal or yeast origin, or a specialized clinical positioning creates a defined market segment.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
2. National Library of Medicine. (2024). DailyMed: Ergocalciferol product labeling. https://dailymed.nlm.nih.gov/dailymed/
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Code. (2024). 21 U.S.C. § 355, New drugs and abbreviated applications. https://uscode.house.gov/
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
6. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/page/quality-guidelines